Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Alcon, Kikkoman, and More

Premium

Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene

Patent Number: 8,334,273

Filed: Dec. 19, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the factor VII gene,” the patent's abstract states.


Title: Lactic Acid Bacteria-Derived Double-Stranded RNA

Patent Number: 8,334,371

Filed: Jan. 26, 2010

Lead Inventor: Ikuko Masuda, Kikkoman

The invention, the patent's abstract states, comprises “an immunoregulator that is safe and efficiently incorporated into cells, along with a production process thereof. ... Double-stranded RNA derived from lactic acid bacteria, an immunoregulator having for an active ingredient thereof double-stranded RNA derived from lactic acid bacteria, and a process for producing double-stranded RNA derived from lactic acid bacteria are provided. Bacteria cells of a strains of lactic acid bacteria such as genus Tetragenococcus, genus Pediococcus, genus Lactobacillus, genus Streptococcus, or genus Leuconostoc are able to produce double-stranded RNA having immunoregulatory action therein.”


Title: Nuclease-Resistant Double-Stranded Ribonucleic Acid

Patent Number: 8,334,373

Filed: March 2, 2011

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

“This invention relates to modified double-stranded oligoribonucleic acid having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene,” according to the patent's abstract.


Title: Low-Density Lipoprotein Receptor-Mediated siRNA Delivery

Application Number: 20120315288

Filed: Aug. 13, 2012

Inventor: Jon Chatterton, Alcon

“The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo,” the patent application's abstract states. “The conjugates comprise a ligand that can bind to a low-density lipoprotein receptor or LDLR family member. Therapeutic uses for the conjugates are also provided.”


Title: Methods and Compositions for Treating Insects

Application Number: 20120316220

Filed: Feb. 2, 2012

Lead Inventor: Donna Ward, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, relates to “methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction, and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors.”


Title: Novel RNAi Therapeutic for Treatment of Hepatitis C Infection

Application Number: 20120316222

Filed: July 26, 2012

Inventor: Hengli Tang, Florida University

The invention comprises “small interfering RNAs or small hairpin RNA … that target human cyclophilin A to inhibit hepatitis C infection,” the patent application's abstract states. “Such siRNAs and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNAs and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing, inhibiting, [and] preventing ... HCV infection using such siRNAs and shRNAs and compositions comprising same are also provided.”

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.